title: Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
abstract: P-glycoprotein modulators are respected to be multidrug resistance reversing agents in cancer chemotherapy. Some calcium channel blockers, calmodulin inhibitors or immunosuppressive agents have been used in clinical studies, although the dose of these drugs required to test in vitro experimental data might cause potent pharmacological effects which are not desirable in patients. By using LLC-GA5-COL150 cells that express P-glycoprotein specifically on the apical membranes, we examined the transport of anticancer drugs mediated by P-glycoprotein. Cepharanthin, a biscoclaurine alkaloid, potently inhibits the transport of vinblastine and daunorubicin, both commonly used anticancer agents. The 50% inhibitory concentration of cepharanthin on daunorubicin transport was 2.06 microM. Combined inhibitory effects on daunorubicin transport were observed when cepharanthin was used together with cyclosporin A, a potent immunosuppressive agent and P-glycoprotein modulator. Cepharanthin itself was transported by P-glycoprotein. Transcellular transport of cepharanthin across LLC-GA5-COL150 cell monolayers was saturable when its concentration was under 5 microM, and the transport was inhibited by P-glycoprotein modulators. These results indicate that cepharanthin can reverse multidrug resistance, and proper combination with other P-glycoprotein modulators could potentiate its inhibitory effect on expelling the anticancer drugs out of the cell via P-glycoprotein.
authors.affiliation: Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hirai
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Shimizu
authors.forename: Y
authors.initials: Y
authors.lastname: Tanigawara
authors.forename: M
authors.initials: M
authors.lastname: Yasuhara
authors.forename: R
authors.initials: R
authors.lastname: Hori
authors.forename: Y
authors.initials: Y
authors.lastname: Kakehi
authors.forename: O
authors.initials: O
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Ueda
authors.forename: T
authors.initials: T
authors.lastname: Komano
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000470:Alkaloids / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics*; D044182:Benzylisoquinolines; D001693:Biological Transport, Active / Q000187:drug effects; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology; D003630:Daunorubicin / Q000493:pharmacokinetics; D018432:Drug Resistance, Multiple; D004357:Drug Synergism; D007700:Kinetics; D014747:Vinblastine / Q000493:pharmacokinetics; D052117:Benzodioxoles
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000470:Alkaloids; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D044182:Benzylisoquinolines; D016572:Cyclosporine; D003630:Daunorubicin; D014747:Vinblastine; C006947:cepharanthine; D052117:Benzodioxoles